Vesicular Glutamate Transporter 3 in age-dependent optic neuropathy by Munguba, Gustavo C. et al.
Vesicular Glutamate Transporter 3 in age-dependent optic
neuropathy
Gustavo C. Munguba, Andrew S. Camp, Miguel Risco, Mary L. Tapia, Sanjoy K. Bhattacharya,
Richard K. Lee
Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL
Purpose: To determine retinal vesicular glutamate transporter 3 (VGLUT3) expression alterations in a mouse model of
progressive optic neuropathy (glaucoma).
Methods: Tissue specimens were obtained from age-matched DBA/2J and control C57BL/6J mice for western blot
analysis. Enucleated globes from DBA/2J, C57BL/6J, and BALB/cJ mice were fixed in formalin, paraffin-embedded, and
sectioned for VGLUT3 protein localization.
Results: western blot analysis of the control retinas revealed the expression of a ~55 kDa immunoreactive VGLUT3
protein that is to be expected in tissues such as retina, brain, liver, heart, and kidney tissue, but not in intestinal or lung
tissue. Furthermore, a strong ~130 kDa immunoreactive VGLUT3 isoform that is restricted to the central nervous system
(the brain and retinas) was also identified in the controls, but was not detected in the DBA/2J retinas. Immunofluorescence
microscopy showed a lack of VGLUT3 expression in the synapses between amacrine and retinal ganglion cells in DBA/
2J retinas, in contrast to its strong expression in the C57BL/6J and BALB/cJ controls.
Conclusions: Our results implicate the dysregulated expression of a central nervous system-specific VGLUT3 isoform
as a predisposing factor in the development of optic neuropathy in DBA/2J mice, a spontaneous mouse model of glaucoma.
In striking parallel to the visual system defects of glaucomatous DBA/2J mice, the inner ear of VGLUT3 knockout mice
displays a progressive loss of inner hair cell to spiral-ganglion neuron synapses. A significant reduction in the number of
spiral-ganglion neurons leads to age-associated deafness. Thus, we propose that the absence of this biochemically
uncharacterized 130 kDa VGLUT3 isoform in the DBA/2J retina is a predisposing factor in synaptic instability, and a
contributing factor in the age-dependent and progressive loss of ganglion cells projecting to the brain.
Glutamate, the major neurotransmitter in the retina, is
loaded into synaptic vesicles by a family of proteins known
as  vesicular  glutamate  transporters  (VGLUTs)  [1].  This
protein  family  consists  of  three  distinct  yet  highly
homologous  genes  that  have  defined  spatial  expression
patterns [2]. In the retina, glutamate transporters provide the
only  means  of  removing  glutamate  from  the  extracellular
space  and  into  cells  [3]  where  VGLUTs  package  this
neurotransmitter  into  vesicles  [4].  Although  the  role  of
VGLUTs in central nervous system (CNS) exocytic release
has been extensively studied [2], VGLUT expression in non-
neuronal tissues such as muscle and liver tissue, have led to
speculation  about  additional  functions  for  these  vesicular
transporters,  such  as  glutamate  buffering  [5].  It  has  been
suggested  that  excessive  stimulation  of  the  glutamatergic
system, “excitotoxicity,” contributes to retinal ganglion cell
(RGC) death in glaucoma [3], the second leading cause of
irreversible blindness worldwide [6].
In the rodent retina, VGLUT3 is expressed by 1% of the
amacrine cell population in the inner plexiform layer (IPL)
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[7]. Whereas both VGLUT1 and VGLUT2 are expressed by
postnatal day 6 (P6) in multiple retinal cell lineages, VGLUT3
is only detected at P10 and is restricted to amacrine, whose
dendritic  arborization  in  the  IPL  expands  P15  [8].  The
presence  of  nonglutamate  neurotransmitters  in  VGLUT3-
expressing cells, whether amacrine cells [7,9], cholinergic
interneurons of the striatum, or serotonin neurons in the raphe
[2], is suggestive of nonclassical roles for these neurons [5].
The role of VGLUT3 in these neuronal synapses is still
largely unknown, and only recently has VGLUT3 been shown
to  mediate  the  regulated  exocytosis  of  glutamate  [10].
Furthermore, unlike the limited axonal targeting properties of
VGLUT1,  VGLUT3  can  also  target  the  cell  body  and
dendrites, and has been implicated in the retrograde synaptic
release of glutamate [11]. While VGLUT3 expression in the
rodent retina is restricted to glycinergic amacrine synapses in
the IPL [12], human retinas express VGLUT3 in ganglion cell
bodies [9]. This marked contrast in subcellular localization
between neighboring neurons of human and rodent retinas
raises the question of whether cells expressing nonglutamate
neurotransmitters may functionally impart a cell-specific role
to VGLUT3.
Deletion  of  the  VGLUT3  gene  does  not  induce
compensatory upregulation of other VGLUTs in neurons that
are traditionally considered to be nonglutamatergic, such as
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413GABAergic, cholinergic, and serotoninergic neurons. Defects
in  the  VGLUT3  gene  have  been  identified  to  cause  a
progressive,  age-associated  form  of  high-frequency,  non-
syndromic deafness (DFNA25), in humans and mice [13].
VGLUT3 knockout (KO) mice, whose inner hair cells (IHCs)
lack VGLUT3 expression, and display a progressive loss of
IHC  to  spiral  ganglion  neuron  (SGN)  synapses  and  a
significant  reduction  in  the  number  of  SGNs  [13].
Furthermore, the ablation of glutamate release through the
deletion of the VGLUT3 gene at the superior olive, where the
corelease  of  glutamate  by  VGLUT3-expressing  inhibitory
neurons  is  well  established.  This  results  in  disrupting
developmental  synapse  elimination  and  impairing  the
strengthening of the connections maintained between neurons
[14].  In  the  zebrafish  “asteroid”  mutant,  the  absence  of
VGLUT3 results in the reduction of synaptic vesicles at ribbon
bodies in IHCs and abolishes post-synaptic action currents
[15]. The importance of VGLUT3 expression in the auditory
system, which has many structural and functional analogs to
the visual system, raises the possibility that this vesicular
glutamate transporter plays a nonredundant role in the retina.
The functional role of VGLUT3 in the retina remains
largely unknown. We addressed this issue by studying the
DBA/2J mouse glaucoma model of age-associated, chronic
progressive optic neuropathy and RGC loss [16]. These mice
develop  age-dependent  progressive  eye  abnormalities,
including elevated intraocular pressure starting at 8–9 months,
severe optic nerve damage, and significant RGC loss by 12
months of age [16-20]. Probing of retinal neuron population
changes in these mice originally revealed an exclusive loss of
RGCs [21]; however, recent studies report changes in the
GABAergic  and  cholinergic  amacrine  cell  populations,
whereas  glycinergic  amacrine  cells,  which  are  known  to
express VGLUT3 [12], are unaffected [22]. Large studies
categorizing  DBA/2J  animal  pathology  have  shown  optic
nerve  degeneration  that  is  variable,  asymmetric,  and
progressive, leading to optic nerve head excavation secondary
to RGC death, a characteristic feature of glaucoma [17].
Here, we report on impaired retinal VGLUT3 expression
in an inbred mouse optic neuropathy model associated with
RGC loss. VGLUT3 expression is absent in synapses between
amacrine  cells  and  RGCs  in  DBA/2J  mice.  Our  findings
implicate  the  dysregulated  expression  of  a  CNS-specific
VGLUT3 isoform as a predisposing factor in the development
of optic neuropathy in DBA/2J mice. In striking parallel to the
visual  system  defects  of  glaucomatous  DBA/2J  mice,  the
inner ear of VGLUT3-KO mice displays a progressive loss of
IHC  to  SGN  synapses,  and  a  significant  reduction  in  the
number of SGNs, leading to age-associated deafness [13].
Thus, we hypothesize that the absence of this biochemically
uncharacterized 130 kDa VGLUT3 isoform in the DBA/2J
retina is a predisposing factor in synaptic instability, and an
age-dependent, progressive contributing factor in the loss of
ganglion  cells  projecting  to  the  brain.  Furthermore,  we
identify a component of DBA/2J retina-specific pathology
and a biochemically isoform type of VGLUT3 that is CNS-
restricted, both previously uncharacterized, to our knowledge.
METHODS
Animals: DBA/2J, C57BL/6J, and BALB-cJ animals were
bred and handled according to the ARVO Statement for the
Use  of  Animals  in  Ophthalmic  and  Vision  Research.  All
animal procedures were approved by the University of Miami
Institutional Animal Care and Use Committee.
Immunofluorescence  and  microscopy:  The  primary
antibodies  used  were  guinea  pig  anti-VGLUT3  (AB5421,
1:4,000 dilution; Chemicon, Temecula, CA) and guinea pig
anti-VGLUT1 (AB5905, 1:1,000 dilution; control not shown
in  figures;  Chemicon).  The  secondary  antibody  used  was
donkey  antiguinea  pig  IgG  Cy5  (706–175–148,  1:100
dilution; Jackson Labs, West Grove, PA). Globes or brains
were fixed using 4% formalin (P1648; Sigma, St. Louis, MO)
in 1X phosphate buffered saline (PBS; 127 mM NaCl, 2.7 mM
KCl,  10  mM  phosphate)  buffer  at  25  °C.  Following
enucleation or dissection and fixation, globes and brains were
embedded in paraffin, sectioned, and mounted on glass slides.
We had sectioned and immunostained slides covering the
entire length of the retina. Each section was cut to a 10 um
thickness, and one out of every 10 slides was used to walk
along the entire retina of two 8-month-old C57BL/6J and
DBA/2J animals. We also immunostained retinas from at least
three different animals at each given age for C57BL/6J and
DBA/2J  mouse  strains,  always  comparing  representative
areas of both the DBA/2J and C57BL/6J control animals. The
age groups used for the C57BL/6J and DBA/2J animals were
9 days, 3 months, 8 months, 12 months, and 19 months. Two
BALB/cJ animals were used as an additional positive control
at three months of age. Brains from two 8-month-old C57BL/
6J and DBA/2J animals were also used as additional controls
for immunostaining. Slides were rehydrated in xylene and
sequential alcohol rinses, then treated at 95 °C with Trilogy
(CMX833-C; Cell Marque, Rocklin, CA) antigen retrieval
reagent.  Tissue  sections  were  subsequently  blocked  with
Rodent Block M (RBM96; BioCare Medical, Concord, CA)
for  30  min  to  reduce  nonspecific  binding.  Slides  were
incubated  overnight  at  4  °C  in  PBS  containing  primary
antibodies, washed with PBS, incubated in antibody buffer
containing secondary antibodies for 1 h at room temperature,
washed with PBS, and mounted onto glass coverslips using
Vectashield with DAPI (Vector, Burlingame, CA). Images
were collected on an inverted microscope (Axiovert 200M;
Carl Zeiss Meditec, Oberkochen, Germany) running the Zeiss
AxioVision 4.7.2 on PC (Zeiss Inc., Thornwood, NY).
Western blot analysis: Tissues were homogenized in radio-
immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1% Igepal, and 0.5% sodium dodecyl
sulfate,  and  0.5%  deoxycholic  acid)  with  complete
miniprotease inhibitors (11836153001; Roche, Indianapolis,
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414IN)  using  a  mechanical  homogenizer  (Polytron  PT1200;
kinematica Inc. Cincinnati, OH). Retinas were homogenized
in RIPA buffer with complete miniprotease inhibitors using a
disposable Kontes Pellet Pestle with cordless motor tissue
grinder  (Kimble  Kontes,  Vineland,  NJ).  Following
homogenization,  tissues  were  passed  through  a  21-gauge
needle six times, and the soluble fraction was used as the
protein lysate. The insoluble fractions were also checked by
western  blot  analysis  (not  shown  in  figures).  Twenty
micrograms of protein were loaded per well for each sample.
The  primary  antibody  used  was  rabbit  anti-VGLUT3
(AB23977, 1:2,500 dilution; Abcam, Cambridge, MA). The
secondary  antibody  used  was  peroxidase-conjugated
AffiniPure Donkey antiguinea pig IgG (H+L; 706–035–148,
1:10,000  dilution;  Jackson  Labs).  The  membranes  were
blocked for 1 h with phosphate-buffered saline with 0.1%
Tween-20 (PBST) containing 5% milk, incubated overnight
at 4 °C in 2% milk in PBST containing primary antibodies,
washed with PBST, incubated in 2% milk in PBST containing
secondary antibodies for 30 min at room temperature, and
washed with PBST and PBS. The chemiluminescent substrate
used was SuperSignal West Pico (34080; Thermo Scientific,
Rockford, IL).
RESULTS
A  130  kDa  central  nervous  system  specific  isoform  of
VGLUT3 is undetectable in DBA/2J retinal tissue: VGLUT3
western  blot  analyses  of  the  control  C57BL/6J  mice
demonstrated  the  expression  of  an  expected  ~55  kDa
immunoreactive protein in tissues such as retina, brain, and
liver tissue, while expression was absent from intestine and
lung tissue (Figure 1A). This VGLUT3 expression pattern was
consistent with previous mRNA (mRNA) expression studies.
We further showed strong VGLUT3 protein expression in the
heart and moderate expression in the kidney.
Surprisingly,  a  strong  ~130  kDa  immunoreactive
VGLUT3 isoform was seen in both the brain and retina tissue
(Figure 1A). This 130 kDa band was substantially brighter
than the expected 55 kDa VGLUT3 band, and was restricted
to CNS tissues. Furthermore, the comparison of DBA/2J and
Figure 1. Central nervous system-specific 130 kDa isoform of vesicular glutamate transporter 3 that is undetectable in DBA/2J retina. Western
blot analysis of C57BL/6J mouse lysates demonstrate expression of an expected vesicular glutamate transporter 3 (VGLUT3) 55 kDa
immunoreactive protein band in brain, heart, liver, kidney and retina tissue, and a strong 130 kDa band restricted to the central nervous system
(brain and retina tissue; A). Immunoreactivity of the 130 kDa VGLUT3 band is undetectable in DBA/2J retinas, while present in DBA/2J
brains (B). The 55 kDa VGLUT3 isoform serves as an internal loading control. Expression levels of the 55 kDa VGLUT3 protein in all tested
tissue samples (including the retina) were comparable to control C57BL/6J animal tissues (B). All wells were loaded with 20 μg of protein
from age-matched eight-month-old animals.
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415control C57BL/6J lysates showed differences in VGLUT3
expression in the retina. DBA/2J retinas lacked expression of
the  CNS-specific  isoform  of  VGLUT3,  based  upon  the
western blot analysis, while robust expression of this isoform
in DBA/2J brain was observed (Figure 1B). While DBA/2J
mice  selectively  expressed  the  CNS-restricted  130  kDa
isoform only in the brain, the expected 55 kDa VGLUT3 band
showed  no  change  in  expression  in  all  the  other  tissues
assayed, including retina tissue (Figure 1B).
VGLUT3 amacrine cell synapses are undetectable in DBA/2J
retinas: The expression pattern of VGLUT3 in the retina was
assessed by immunofluorescence. A lack of any VGLUT3
immunofluorescence signal specific to the IPL of the DBA/2J
retinas was corroborated by the absence of expression found
by western blot analysis of the 130 kDa VGLUT3 isoform.
We assessed whether or not the lack of DBA/2J VGLUT3
immunostaining  had  a  different  temporal  pattern  by
immunostaining DBA/2J retinas from as early as P9 to as late
as 19 months of age. Sections along the entire length of the
retina were analyzed for both DBA/2J and C57BL/6J globes.
VGLUT3  immunostaining  was  undetectable  at  any  cross-
section  along  the  DBA/2J  retinas  at  all  ages  examined,
whereas robust VGLUT3 immunostaining was observed in all
cross-sections along the IPL of the control C57BL/6J and
BALB/cJ retinas (Figure 2A-D). Immunostaining of DBA/2J
and  C57BL/6J  brain  slices  showed  robust  VGLUT3
immunoreactivity in both strains (Figure 2E,F).
DISCUSSION
Our data show that VGLUT3 expression can be modulated in
a tissue-specific manner providing the CNS (retina and brain)
with  a  unique,  and  up  to  now  uncharacterized,  130  kDa
isoform of VGLUT3, in addition to the known 55 kDa isoform
of  VGLUT3.  The  absence  of  the  CNS-specific  VGLUT3
isoform  in  DBA/2J  retinas,  but  not  in  the  brain,  also
demonstrates that VGLUT3 isoforms in brains and retinas are
modulated  independently.  Our  results  suggest  that  this
previously  uncharacterized  high  molecular  weight,  CNS-
specific, VGLUT3 isoform is the primary VGLUT3 species
residing at CNS synapses. This result is corroborated by the
lack of a VGLUT3 immunofluorescence signal specific to the
inner plexiform layer of DBA/2J retinas, in association with
the lack of expression of the 130 kDa VGLUT3 isoform found
by western blot analysis.
Work  by  Schafer  and  colleagues,  who  cloned  and
characterized VGLUT3 from P1 mouse brain tissue, attribute
several broad protein bands observed by western blot analysis
to  the  presence  of  possible  dimerization  products  or
nonspecific aggregation or processing artifacts from vaccinia-
infected  cells.  In  their  work,  Schafer  et  al.  [18]  identify
glycosylation  and  phosphorylation  sites,  suggesting  the
possibility that posttranslational modifications contribute to
this  higher  molecular  weight  isoform  of  VGLUT3.
Alternative  splicing  of  the  VGLUT3  gene  is  yet  another
explanation that cannot be excluded. In contrast to our finding
of VGLUT3 protein expression in the kidney, northern blot
analysis experiments by Schafer and colleagues revealed no
VGLUT3 hybridization in a 4.9 kb mRNA probe of kidney
mRNA, while observing several liver-derived mRNA species,
thereby supporting the likelihood of alternative splicing as an
explanation for the 130 kDa VGLUT3 isoform [23].
Focal VGLUT3 expression in the retina has previously
been  attributed  to  synaptic  vesicles  in  subpopulations  of
amacrine cells [5,7,12]. Johnson and colleagues observed the
presence of VGLUT3 retinal protein beginning at P8, which
achieved an adult expression pattern by P12 [12]. The 55 kDa
isoform  of  VGLUT3,  but  not  the  130  kDa  isoform,  is
detectable  in  DBA/2J  retinas  by  western  blot  analysis.
Although DBA/2J retinas express the lower molecular weight
VGLUT3  isoform,  immunofluorescence  signals  are
undetectable  at  amacrine  cell  synapses.  Furthermore,
immunostaining  of  DBA/2J  brain  slices  show  the  robust
immunoreactivity of VGLUT3, corroborating the presence of
the 130 kDa isoform by western blot analysis. These data
suggest  VGLUT3  species  may  play  distinctive  roles  in
different cell types. In association with observed changes in
amacrine cell populations of DBA/2J animals, it is possible
that the VGLUT3 amacrine cell population may be entirely
absent in DBA/2J retinas, compared to other mouse strains.
This  is  unlikely,  however,  because  comparisons  between
DBA/2J and C57BL/6J mouse retinas either have suggested
cell loss restricted to the RGC layer [21] or have excluded any
changes to glycinergic amacrine cells, previously identified
as a VGLUT3 amacrine cell [22] subpopulation in the DBA/
2J strain [12].
The inner ear has striking similarities to the retina. IHCs
of the inner ear function as mechanoelectrical transducers
conveying  auditory  signals  through  SGNs  (analogous  to
RGCs in the retina) to the CNS. SGNs receive auditory signals
from IHCs and relay these signals to the brain via long axons
consisting of the eighth cranial nerve. While spiral ganglia
express  N-methyl-D-aspartate  (NMDA),  α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate  (AMPA),  and
kainate  receptors,  the  functional  distinction  of  individual
receptors  and  their  roles,  using  selective  AMPA  receptor
agonists and other methods, suggests a predominant role for
AMPA receptors in IHC-mediated neurotransmission to the
CNS,  thereby  implicating  glutamate  as  an  important
neurotransmitter  in  auditory  neurotransmission  [24].  The
expression  of  various  receptors  by  spiral  ganglia  is  not
surprising, considering that VGLUT3 is the only VGLUT
expressed by IHCs that signals directly to SGNs. Like neurons
in the retina, auditory neurons are also sensitive to glutamate-
mediated excitotoxicity, and are also dependent on active
synaptic inputs for survival.
Defects in the VGLUT3 gene have been identified the
cause of a progressive, age-associated form of high-frequency
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416Figure 2. Vesicular glutamate transporter 3 amacrine cell synapses that are undetectable in DBA/2J retinas. Representative globe cross-sections
immunostained with vesicular glutamate transporter 3 (VGLUT3) antibody show VGLUT3 expression in the retinal inner plexiform layer.
Immunostaining shows VGLUT3 (red) expression in the control C57BL/6J (C), and BALB/c (D) retinas, while young nonglaucomatous DBA/
2J (A) or old glaucomatous DBA/2J (B) VGLUT3 expression levels are undetectable. Nuclear DAPI staining (blue) is also shown. Merge
represents the combination of Blue and Red channels. Expression was assessed in animals ranging from postnatal day 8 to 21 months of age.
Immunostaining of DBA/2J (E) and C57BL/6J (F) tissue shows VGLUT3 (red) expression in the brain of both animal strains.
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417nonsyndromic deafness, DFNA25 [13]. VGLUT3-KO mice,
whose IHCs lack VGLUT3 expression, display a progressive
loss of IHC-to-SGN synapses, and a significant reduction in
the  number  of  SGNs  [13].  Interestingly,  age-related,
progressive hearing loss has also been implicated in the DBA/
2J progressive glaucoma model [25]. DBA/2J animals possess
the ahl mutation cadherin 23 [25] and a fascin-2 gene mutation
[26] whose combined effect results in early-onset hearing loss
[27,28]. Because age-related hearing loss is a multifactorial
disease process, with many similarities to glaucomatous optic
neuropathy, it is tempting to speculate that the lack of the
CNS-specific 130 kDa VGLUT3 isoform in the visual system
might also repeat itself in the auditory synapses, providing yet
another contributor to progressive hearing loss, though this
has  not  yet  been  investigated.  Parallels  between  the
progressive  loss  of  glaucomatous  DBA/2J  RGCs  and  the
progressive  loss  of  the  auditory  CNS-projecting  SGNs  of
VGLUT3-KO mice may be indicative of similar molecular
pathophysiological mechanisms. In both cases, perturbation
of VGLUT3 integrity in cells making direct synapses to CNS-
projecting  ganglia—RGCs  in  glaucoma  and  SGNs  in
DFNA25  progressive  deafness—is  associated  with  a
progressive loss of synaptic stability and results in age-related
and irreversible first-order neuron loss.
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